Targeting AXL in NSCLC is a research paper published in Lung Cancer Targets and Therapy (2021). On theSindex it has a DataRank of 0. It has been cited 16 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: 5R01CA211052-03
Optimizing biologically-based rational polytherapy in ALK+ lung cancer
National Institutes of Health
Grant: 5R01CA169338-02
Rational Combined Inhibition of NF-kB and EGFR to Optimize Lung Cancer Treatment
National Institutes of Health
Grant: 1R01CA204302-01A1
Characterization of YAP as a rational companion target in lung cancer
National Institutes of Health
Grant: 5R01CA231300-03
(PQ7) Defining a new mode of RAS signaling in cancer from cytoplasmic protein granules
National Institutes of Health
Grant: 3U54CA224081-01S1
Bay Area Team Against Resistance
NCI NIH HHS
Grant: U54 CA224081
NCI NIH HHS
Grant: R01 CA211052
NCI NIH HHS
Grant: T32 CA108462
NCI NIH HHS
Grant: R01 CA204302
NCI NIH HHS
Grant: R01 CA231300
NCI NIH HHS
Grant: R01 CA169338
Fields of Study
Keywords
Sustainable Development Goals